araag2/HINT huggingface dataset:
Clinical trial NCT02098993 (phase 2, status: terminated)
Conditions: acute chest syndrome, sickle cell disease
ICD codes: D57.1, D57.20, D57.212, D57.219, D57.211, D57.213, D57.218
Drugs: unfractionated heparin
SMILES: O.O.[Al+3].[Cl-].[Zr+4].NCC([O-])=O
Reason stopped: 
    poor enrollment.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Diagnosis of ACS defined as a new pulmonary infiltrate involving at least one segment
             of the lung on a chest x-ray or chest CT scan with 2 or more of the following: chest
             pain, tachypnea, dyspnea, cough, hypoxemia, or body temperature greater than or equal
             to 38.0 degrees Celsius

          -  Hemoglobin electrophoresis confirming HbSS, SC, or B0 (historical records sufficient)

          -  Age greater than or equal to 18

        Exclusion Criteria:

          -  Any absolute contraindication to heparin

          -  Platelet count less than 50 per microliter (current admission)

          -  Historical diagnosis of moyamoya disease as documented in medical records

          -  Historical diagnosis of proliferative retinopathy as documented in medical records

          -  Current participation in a chronic exchange transfusion program

          -  Underlying hypercoagulable disorder other than sickle cell disease

          -  Currently receiving therappeutic anticoagulation

          -  Currently receiving antiplatelet agents

          -  Currently receiving estrogen containing oral contraceptives

          -  Chest CT scan documented PE performed as standard of care prior to study enrollment
             (current admission)
Clinical trial NCT02100748 (phase 2, status: completed)
Conditions: acute pain
ICD codes: G89.12, G89.18, G89.11, G89.3
Drugs: trv130, morphine, placebo
SMILES: CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Has undergone primary, unilateral, first metatarsal bunionectomy (osteotomy and
             internal fixation) with no additional collateral procedures.

          -  Experiences a pain intensity rating of ≥ 4 on an 11 point NRS

          -  Able to provide written informed consent before any study procedure.

        Exclusion Criteria:

          -  ASA Physical Status Classification System classification of P3 or worse

          -  Has surgical or post-surgical complications.

          -  Has clinically significant medical conditions or history of such conditions that may
             interfere with the interpretation of efficacy, safety, or tolerability data obtained
             in the trial, or may interfere with the absorption, distribution, metabolism, or
             excretion of drugs.

          -  Has previously participated in another TRV130 clinical study.
Clinical trial NCT02102490 (phase 2, status: completed)
Conditions: metastatic breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: abemaciclib
SMILES: CCN1CCN(CC2=CC=C(NC3=NC=C(F)C(=N3)C3=CC(F)=C4N=C(C)N(C(C)C)C4=C3)N=C2)CC1
Eligibility criteria:

        Inclusion Criteria.

          -  Have a diagnosis of Hormone Receptor Positive (HR+), Human Epidermal Growth Factor
             Receptor 2 Negative (HER2-) breast cancer.

          -  Recurrent, locally advanced, unresectable or metastatic breast cancer with disease
             progression following anti-estrogen therapy.

          -  Prior treatment with at least 2 chemotherapy regimens:

               -  At least 1 of these regimens must have been administered in the metastatic
                  setting.

               -  At least 1 of these regimens must have contained a taxane.

               -  No more than 2 prior chemotherapy regimens in the metastatic setting.

          -  Have a performance status (PS) of 0 to 1 on the Eastern Cooperative Oncology Group
             scale.

          -  Have discontinued all previous therapies for cancer.

          -  Have the presence of measureable disease as defined by Response Evaluation Criteria in
             Solid Tumors Version 1.1.

        Exclusion Criteria:

          -  Have either a history of central nervous system (CNS) metastasis or evidence of CNS
             metastasis on the magnetic resonance image of brain obtained at baseline.

          -  Received prior therapy with another cyclin-dependent kinases 4 and 6 (CDK4/6)
             inhibitor.

          -  Have received treatment with a drug that has not received regulatory approval for any
             indication within 14 or 21 days of the initial dose of study drug.

          -  Have had major surgery within 14 days of the initial dose of study drug.

          -  Have a history of any other cancer (except non-melanoma skin cancer or carcinoma
             in-situ of the cervix).
Clinical trial NCT02104583 (phase 2, status: completed)
Conditions: ventricular arrhythmia
ICD codes: I47.0
Drugs: eleclazine, placebo to match eleclazine
SMILES: FC(F)(F)OC1=CC=C(C=C1)C1=CC=C2OCCN(CC3=NC=CC=N3)C(=O)C2=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Key Inclusion Criteria:

          -  Have an ICD or CRT-D implanted for primary or secondary prevention and at least one
             ICD intervention for ventricular tachycardia/ventricular fibrillation (VT/VF) [shock
             or ATP] within 60 days prior to screening or a documented VT/VF episode (prior to
             implantation) within 60 days prior to screening

          -  Use of highly effective contraception methods if female of childbearing potential or
             sexually active male

          -  Must be hemodynamically stable

        Key Exclusion Criteria:

          -  New York Heart Association (NYHA) Class IV heart failure

          -  Myocardial infarction, unstable angina, coronary artery bypass graft (CABG) surgery or
             percutaneous coronary intervention (PCI) within 4 weeks prior to screening or during
             the screening period before randomization

          -  Hemodynamically significant primary obstructive valvular disease

          -  History of congenital heart disease

          -  Inherited arrhythmia such as Brugada syndrome. Individuals with long QT syndrome Type
             3 (LQT-3) or hypertrophic cardiomyopathy (HCM) may be considered.

          -  Individuals who are being considered for cardiac transplantation and are on a cardiac
             transplant list

          -  History of seizures or epilepsy

          -  Cardiac ablation within 3 months prior to screening or planned cardiac ablation during
             the study

          -  Severe renal impairment

          -  Abnormal liver function tests

          -  Currently taking Class I and Class III antiarrhythmic drugs; such medications should
             be discontinued 5 half-lives (or 28 days for chronic use of amiodarone) prior to
             randomization

          -  Currently taking drugs or products that are strong inhibitors or inducers of CYP3A;
             such medications should be discontinued 5 half-lives prior to randomization

          -  Currently taking ranolazine; ranolazine should be discontinued at least 7 days prior
             to randomization

          -  Females who are pregnant or are breastfeeding

          -  Individuals with a subcutaneous ICD

          -  Body mass index (BMI) ≥ 36 kg/m^2

        Note: Other protocol defined Inclusion/Exclusion criteria may apply
Clinical trial NCT02105012 (phase 2, status: completed)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: bd mdi 320 µg, bd mdi 160 µg, bd mdi 80 µg, bd mdi 40 µg, placebo mdi
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  ≥ 18 - 65 years of age

          -  Diagnosis of mild to moderate persistent asthma, diagnosed at least 6 months prior to
             screening

          -  Currently receiving treatment with a low to medium dose of an inhaled corticosteroid
             (ICS) OR a combination of controller medications for at least 4 weeks preceding
             screening

          -  Pre-albuterol FEV1 of > 60% and < 85% of predicted normal value

          -  Reversibility: Increase in FEV1 of ≥ 12% and ≥ 200 mL over the pre-albuterol FEV1
             within 30 - 60 minutes after the inhalation of 4 puffs of Ventolin hydrofluoroalkane
             (HFA)

          -  Asthma Symptom Criteria: Have required albuterol use on at least two of the last seven
             days and have an Asthma Control Questionnaire (ACQ) total score ≥ 1.5 prior to
             Randomization

        Exclusion Criteria:

          -  Life-Threatening Asthma: A subject must not have life-threatening asthma defined as a
             history of significant asthma episode(s) requiring intubation associated with
             hypercapnia, respiratory arrest, hypoxic seizures, or asthma-related syncopal
             episode(s) within the 12 months prior to screening

          -  Worsening of Asthma: A subject must not have experienced a worsening of asthma which
             involved an emergency department visit, hospitalization or use of oral/parenteral
             corticosteroids within 6 weeks of screening

          -  Intermittent, Seasonal, or Exercise-Induced Asthma Alone: Subjects with only
             intermittent, seasonal or exercise-induced asthma are excluded from participation in
             this study

          -  Concurrent Respiratory Disease

          -  Pregnant women or nursing mothers

          -  A current diagnosis of Chronic Obstructive Pulmonary Disease (COPD

          -  Current smokers or subjects with a > 10 pack year history of cigarettes, cigars, or
             pipe smoking

          -  Respiratory tract infection within 6 weeks prior to Visit 1

          -  Subjects with documented myocardial infarction within a year from screening visit

          -  Clinically significant abnormal ECG

          -  Abnormal liver function tests defined as aspartate aminotransferase (AST), alanine
             aminotransferace (ALT), alkaline phosphatase or total bilirubin ≥ 1.5 times upper
             limit of normal on repeat testing

          -  Subjects who have cancer that has not been in complete remission for at least 5 years

          -  Drug Allergy: Subjects who have a history of hypersensitivity to any component of the
             metered-dose inhaler (MDI)
Clinical trial NCT02109016 (phase 2, status: terminated)
Conditions: non-small cell lung cancer, squamous non-small cell lung cancer, nsclc, small cell lung cancer, sclc, lung cancer, advanced lung cancer, metastatic lung cancer, stage iv lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2, C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: lucitanib
SMILES: CNC(=O)C1=C2C=CC(OC3=C4C=C(OC)C(OCC5(N)CC5)=CC4=NC=C3)=CC2=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically confirmed advanced/metastatic SCLC or NSCLC

          -  Any of the following tumor tissue based genetic alterations: FGFR1, FGFR2, FGFR3,
             VEGFA, or PDGFRα amplification; Any FGFR1, FGFR2, or FGFR3 gene fusion; FGFR1, FGFR2,
             or FGFR3 activating mutation

          -  Availability of tumor tissue sample suitable for the central confirmation of the
             genetic alteration and exploratory analyses

          -  Eastern Cooperative Oncology Group (ECOG) of 0 or 1

          -  Measurable disease per RECIST 1.1

          -  Documented radiographic disease progression following at least one line of therapy in
             the advanced/metastatic setting

        Exclusion Criteria:

          -  Tumors that are invading a major vessel; NSCLC tumors abutting to a major vessel

          -  Uncontrolled hypertension, defined as SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg with
             optimized anti-hypertensive therapy

          -  Uncontrolled hypothyroidism defined as serum thyroid stimulating hormone (TSH) higher
             than 5 mIU/mL while receiving appropriate thyroid hormone therapy

          -  Symptomatic and/or untreated central nervous system metastases

          -  Presence of another active cancer

          -  Ongoing adverse events from surgery or prior anti-cancer therapies, including
             radiation, targeted, or cytotoxic therapies

          -  Pregnant or breastfeeding women
Clinical trial NCT02109445 (phase 2, status: terminated)
Conditions: metastatic cancer pancreas
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: pf-03084014, gemcitabine, nab-paclitaxel, pf-03084014, gemcitabine, nab-paclitaxel, gemcitabine, nab-paclitaxel
SMILES: CCC[C@H](N[C@H]1CCC2=CC(F)=CC(F)=C2C1)C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, CCC[C@H](N[C@H]1CCC2=CC(F)=CC(F)=C2C1)C(=O)NC1=CN(C=N1)C(C)(C)CNCC(C)(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@]12[C@H](OC(=O)C3=CC=CC=C3)[C@]3(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)C4=CC=CC=C4)C4=CC=CC=C4)C(C)=C([C@@H](OC(C)=O)C(=O)[C@]1(C)[C@@H](O)C[C@H]1OC[C@@]21OC(C)=O)C3(C)C
Reason stopped: 
    the study was terminated on 24jun15 due to change in strategy of pf-03084014 development.no
    safety/efficacy concerns were behind the reason of trial termination
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically or cytologically diagnosis of metastatic ductal adenocarcinoma of the
             pancreas.

          -  No prior radiotherapy, surgery chemotherapy or investigational therapy for metastatic
             disease. Prior adjuvant therapy with 5-FU or gemcitabine (± gemcitabine post
             radiation) administered as radiosensitizer allowed, provided at least 6 months have
             elapsed between the last dose and study registration

          -  Tumor tissue available (Archival 6 months old or de novo biopsy)

          -  Measurable disease as per RECIST 1.1

          -  Performance Status (ECOG) 0 or 1

        Exclusion Criteria:

          -  Symptomatic brain metastases requiring steroids

          -  Prior therapy with gamma secretase inhibitors or other Notch pathway inhibitor

          -  Major surgery within 4 weeks of registration in the current study

          -  Known hypersensitivity to gemcitabine or nab-paclitaxel or any of the excipients

          -  Current or anticipated need for food or drugs that are strong/moderate CYP3A4
             inhibitors or inducers

          -  Diagnosis of any second malignancy within 3 years prior to registration
Clinical trial NCT02110303 (phase 2/phase 3, status: completed)
Conditions: coronary artery disease
ICD codes: I25.10, I25.110, I25.119, I25.111, I25.118
Drugs: ticagrelor, placebo
SMILES: [H][C@@](N1CCC2=C(C1)C=CS2)(C(=O)OC)C1=CC=CC=C1Cl, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged ≥40 years with angiographically proven multivessel coronary artery
             disease defined as at least two major epicardial vessels with any combination of
             either (a) >50% luminal stenosis, or (b) previous revascularization (percutaneous
             coronary intervention or coronary artery bypass graft surgery).

          -  Provision of informed consent prior to any study specific procedures

        Exclusion Criteria:

          -  An acute coronary syndrome within the last 12 months

          -  An indication for dual anti-platelet therapy, such as drug eluting stent

          -  Inability to take aspirin

          -  Receiving thienopyridine therapy such as clopidogrel or prasugrel

          -  Percutaneous coronary intervention or coronary artery bypass graft surgery within the
             last 3 months

          -  Inability or unwilling to give informed consent

          -  Woman with child-bearing potential and who are breastfeeding will not be enrolled into
             the trial (woman who have experienced menarche, are pre-menopausal, have not been
             sterilised or who are currently pregnant)

          -  Known hypersensitivity to ticagrelor or one of its excipients

          -  Active pathological bleeding or bleeding diathesis

          -  Significant thrombocytopenia: <100 x 10^9 /L

          -  History of intracranial haemorrhage

          -  Moderate to severe liver impairment (Child's Grade B or C)

          -  Maintenance therapy with strong cytochrome P450 3A4 (CYP3A4) inhibitors, such as
             ketoconazole, nefazodone, ritonavir, indinavir, atazanavir, or clarithromycin

          -  Major intercurrent illness or life expectancy <1 year

          -  Renal dysfunction (eGFR ≤30 mL/min/1.73 m2)

          -  Contraindication to iodinated contrast agents

          -  Planned coronary revascularization or major non-cardiac surgery in the next 12 months

          -  Maintenance therapy with simvastatin at doses greater than 40mg daily

          -  Receiving oral anticoagulants including warfarin, rivaroxaban, dabigatran or apixaban.
Clinical trial NCT02111096 (phase 2, status: terminated)
Conditions: diabetes mellitus, type 2
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: ly2409021, sitagliptin, placebo, metformin, sulfonylurea
SMILES: CC1=CC(O[C@@H](CCC(F)(F)F)C2=CC=C(C=C2)C(=O)NCCC(O)=O)=CC(C)=C1C1=CC=C(C=C1)C(C)(C)C, N[C@@H](CC(=O)N1CCN2C(C1)=NN=C2C(F)(F)F)CC1=CC(F)=C(F)C=C1F, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CSCC[C@H](N)C(O)=O, [H][C@]1(C)CC[C@@]([H])(CC1)N=C(O)NS(=O)(=O)C1=CC=C(CCN=C(O)N2CC(C)=C(CC)C2=O)C=C1
Reason stopped: 
    the overall benefit-risk profile did not support continued development of ly2409021 for type 2
    diabetes.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Have been treated with a stable dose of metformin for at least 3 months and have been
             treated with an optimally effective and stable dose of an sulfonylurea for at least 6
             months prior to screening.

          -  HbA1c value between 7.0% and 10.0%, inclusive.

          -  Body mass index (BMI) between 20 and 45 kilograms/square meter (kg/m^2), inclusive.

        Exclusion Criteria:

          -  Known type 1 diabetes mellitus.

          -  More than 1 episode of severe hypoglycemia within 6 months prior to screening.

          -  Two or more emergency room visits or hospitalizations due to poor glucose control in
             the 6 months prior to screening.

          -  Severe gastrointestinal disease that may significantly impact gastric emptying or
             motility or having undergone gastric bypass or gastric banding surgery.

          -  Previous history or active diagnosis of pancreatitis.

          -  Positive hepatitis B surface antigen or hepatitis C antibody.

          -  Clinical signs or symptoms of liver disease, or hepatic aminotransferases
             (aminotransferase or alanine aminotransferase) greater than 2.0× upper limit of normal
             (ULN) or elevated alkaline phosphatase (greater than ULN) unrelated to bone metabolic
             disease.

          -  Elevated total bilirubin level (greater than ULN), clinically suspicious
             signs/symptoms of cirrhosis or history of cirrhosis.

          -  Current diagnosis, personal history of neuroendocrine tumors, family history of any
             type of multiple endocrine neoplasia (MEN), or Von Hippel-Lindau.

          -  Contraindications for magnetic resonance imaging.
Clinical trial NCT02112045 (phase 2, status: terminated)
Conditions: multiple myeloma
ICD codes: C90.01, C90.02, C90.00
Drugs: granix, high dose melphalan (hdr)
SMILES: N[C@@H](CC1=CC=C(C=C1)N(CCCl)CCCl)C(O)=O
Reason stopped: 
    terminated due to results of interim analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Symptomatic multiple myeloma requiring treatment

          -  Received at least two cycles of any regimen as initial systemic therapy for multiple
             myeloma and are within 2-12 months of the first dose of initial therapy

          -  At least 18 years of age

          -  Adequate autologous stem cell collection, defined as an unmanipulated, cryopreserved,
             peripheral blood stem cell collection containing at least 2 × 10^6 CD34+ cells/kg
             based on patient body weight.

          -  Adequate organ function as measured by:

               -  Cardiac function: Left ventricular ejection fraction at rest ≥40%

               -  Hepatic function: Bilirubin ≤2 × ULN and aspartate amino transferase/alanine
                  amino transferase (AST/ALT) ≤3 × ULN

               -  Renal function: Creatinine clearance ≥40 mL/minute (measured or
                  calculated/estimated)

               -  Pulmonary function: Carbon monoxide diffusing capacity (DLCO; corrected for
                  hemoglobin [Hgb]), forced expiratory volume in 1 second (FEV1), forced expiratory
                  vital capacity (FVC) ≥50% of predicted value

               -  Oxygen saturation ≥92% on room air

          -  Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2.

          -  Able to understand and willing to sign an IRB-approved written informed consent
             document

        Exclusion Criteria:

          -  Evidence of multiple myeloma disease progression (as defined by IMWG) any time prior
             to ASCT

          -  Prior stem cell transplant (autologous or allogeneic)

          -  Smoldering MM not requiring therapy

          -  Plasma cell leukemia

          -  Systemic amyloid light chain amyloidosis

          -  Active bacterial, viral, or fungal infection

          -  Seropositive for human immunodeficiency virus (HIV)

          -  Known, active hepatitis A, B, or C Infection

          -  Pregnant or breastfeeding.

          -  Receiving other concurrent anticancer therapy (including chemotherapy, radiation,
             hormonal treatment, or immunotherapy, but excluding corticosteroids) within 7 days
             prior to the ASCT or planning to receive any of these treatments prior to the last
             study visit on Day +100.

          -  Hypersensitive or intolerant to any component of the study drug(s) formulation

          -  Receiving growth factors (filgrastim, XM02-filgrastim, peg-filgrastim, plerixafor,
             etc) or undergoing apheresis < 14 days prior to the start of treatment on protocol
             (Day -7).